[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019
Citations66943934
h-index2721
i10-index20292

..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Registered in

AWT IMAGE

AWT IMAGE

..
:: Volume 21, Issue 7 (2-2014) ::
Journal of Ilam University of Medical Sciences 2014, 21(7): 169-177 Back to browse issues page
Analysis of Thraputic Expenditure in Patients with Multiple Sclerosis in Iran
A Eimani , M Golestani , A Omrani , M Ali khani * 1, M Delpasand , R Vafaee , A Mozafari
1- , imani58@yahoo.com
Abstract:   (13188 Views)
Introduction: Aim of the study was to evaluate the cost of four disease-mod-ifying drugs (DMDs) used as first-line treatment for relapsing and remitting mu-ltiple sclerosis (MS): IFNβ-1a IM injecti-on (Avonex®), IFN β-1b SC injection (Betaferon®), IFNβ-1a SC injection (Rebif®) and IFNβ-1a IM injection (CinnoVex®). Materials & Methods: The study used the cost-of-illness approach to estimate the direct and indirect costs associated with five treatment regimes of MS. 231 patie-nts were divided into five groups (groups A, B, C and D received different continu-ous interferon therapy and Group E received symptom management treatm-ent). Detailed questionnaires were com-pleted for 231 patients over a 6-month period (12 months for hospitalization costs). Findings: The annual average of total cost per patient amounted to 24475 USD in 2011. Direct costs amounted to 16945 USD and constituted the largest share of total cost (67.5%). Among the direct costs, the largest cost was belonging to DMDs. Indirect costs amounted to 7530 USD and constituted 32.2% of total cost. Indirect costs were domiately related to leaving the job. Total costs per patient were estimated to be 22881,35850, 32920,15680 and 15042 USD for A, B, C, D and symptom management groups, re-spectively. Discussion & Conclusion: Results of this study indicated that MS imposes subs-tantial economic burden on MS patients, on their families, and on society as a whole. In order to minimize MS costs and improve quality of life, the ideal aim of MS treatment should be directed to early stage of the disease and using cost-effec-tive therapy regims.
Keywords: Cost analysis, disease-modif-ying drugs, multiple sclerosis
Full-Text [PDF 417 kb]   (7708 Downloads)    
Type of Study: case report | Subject: nurse
Received: 2014/02/18 | Accepted: 2014/02/18 | Published: 2014/02/18
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

eimani A, golestani M, omrani A, ali khani M, delpasand M, vafaee R et al . Analysis of Thraputic Expenditure in Patients with Multiple Sclerosis in Iran. J. Ilam Uni. Med. Sci. 2014; 21 (7) :169-177
URL: http://sjimu.medilam.ac.ir/article-1-1594-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 7 (2-2014) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4657